Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Fall 2021 Conference
CANTON, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly® AM, Affinity®, Apligraf®, and NuShield® product lines will be showcased at the 2021 Symposium on Advanced Wound Care (SAWC) Fall Conference held October 29-31 in Las Vegas, Nev.
Attendees of this year’s event are encouraged to visit the Organogenesis-supported lunch symposium, “New Scientific Data Supporting the Use of an Antimicrobial Native Collagen ECM and Real-World Case Studies Highlighting a Treatment Algorithm Approach” held Friday, Oct. 29, from 11:40 a.m. - 1:10 p.m. PST in the Innovation Theatre.
The lunch symposium will feature a presentation by Katie Mowry, Ph.D, Assistant Vice President of Research and Development at Organogenesis, who will present in vivo data that supports the use of the company’s PuraPly technology as an antimicrobial barrier in the early stages of the healing process. Attendees will also hear from Dan Kapp, MD of Palm Beach Gardens Medical Center, who will share his clinical experience using innovative solutions to improve outcomes in complex wounds. Dr. Kapp is the Division Director of Plastic Surgery and Past Chief of Surgery at Palm Beach Gardens Medical Center and a Diplomate of the American Board of Plastic Surgery.
As a lead sponsor of this year's meeting, Organogenesis will also support the presentation, “Leveraging Dermal Substitutes Post-Mohs Surgery: An Exploration of Surgical Technique and Post-Surgery Wound Care” held Saturday, Oct. 30, from 7:30 a.m. – 9 a.m. PST. Anthony Benedetto, DO, FACP, founder and medical director of the Dermatologic SurgiCenter in Philadelphia, will present his experience using dermal substitutes in Post-Mohs surgeries and post-surgery wound care.
Attendees are encouraged to visit the Organogenesis exhibit hall booth (#501) to learn more about the latest advanced wound care products and latest studies. The Organogenesis Adjustable Curette will be available for debridement demonstrations and hands-on experience. Featuring a dual-edge adjustable blade, built-in ruler and contoured grip, this new product aims to elevate the standard of care for wound debridement.
The booth will be open during the following hours:
Fri., Oct 29 4:45 - 6:45 p.m. PST
Sat., Oct 30 12:30 - 3:00 p.m. PST
Sun., Oct. 31 12:30 - 2:00 p.m. PST
POSTER PRESENTATIONS OF INTEREST INCLUDE:
A Comparative Effectiveness Research Study of a Bilayered Living Cellular Construct and Two Skin Grafts for Use in Venous Leg Ulcers
Sabolinski ML, Archambault T
A Comparative Effectiveness Research Study of a Bilayered Living Cellular Construct and Two Placental Allografts for Use in Venous Leg Ulcers
Sabolinski ML, Archambault T
Characterizing the Protein Content of a Dehydrated Amnion Chorion Membrane
Greb L, Kammer M, McQuilling JP, Burnette M, Mowry K
Diabetic Foot Ulcer Patients Receiving Purified Native Type I Collagen Plus Polyhexamethylene Biguanide (PHMB) Antimicrobial Have More Complex Profiles than Standard Wound Care
Desai U, Rice B, Westermeyer B, Zacharia N, Kirsner RS
Starting with Targeting Biofilm and Finishing with Placental Allografts: Clinical Results in 62 Diverse Etiology Wounds
Early Biofilm Management Followed by Dehydrated Placental Allografts for Definitive Management of Postoperative Large Mohs Wounds
Evaluation of a Collagen Matrix with Polyhexamethylene Biguanide Reducing Methicillin Resistant Staphylococcus Aureus Infections Using a Porcine Deep Dermal Wound Model
Davis SC, Li J, Gil J, Solis M, Higa A, Simms C, Raut V
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only to the date of this release, and Organogenesis undertakes no obligations to update or revise these statements, except as may be required by law.
Press and Media Inquiries: Lori Freedman firstname.lastname@example.org Investor Inquiries: Westwicke Partners Mike Piccinino, CFA OrganoIR@westwicke.com 443-213-0500